Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biovica International publ : initiates a collaboration with Mayo Clinic to study DiviTum for the on-treatment monitoring of metastatic breast cancer patients receiving CDK 4/6 inhibitors

04/08/2020 | 02:01am EST

Biovica and Mayo Clinic have entered into an agreement to study the clinical benefit of using DiviTum[®] as a blood-based test, monitoring the tumor response to therapy in patients with metastatic breast cancer.

The main purpose of including DiviTum[®] in studies performed at Mayo Clinic is to evaluate the changes in serum thymidine kinase activity, measured by DiviTum[®], in patients with hormone positive metastatic breast cancer treated with today's standard regimens - including CDK 4/6 inhibitors. DiviTum[® ]measurements at the start of therapy and during treatment will be correlated to patient outcome focusing on the use of DiviTum[® ]as a tool for easy and early evaluation of tumor progression and overall patient survival.

"We are very pleased to collaborate with Mayo Clinic in our ambition to further strengthen our already solid documentation of the value DiviTum[®] can bring to patients being treated for metastatic breast cancer.  This collaboration complements our previous studies in this field and will be important in our market introduction of DiviTum® as a tool for the monitoring of patient response to treatments within metastatic breast cancer" says Anders Rylander, CEO Biovica.

About DiviTum[®]
DiviTum[®] is an innovative biomarker assay developed with the aim to predict outcome and monitor treatment response in cancer therapy. The test measures the activity of the enzyme thymidine kinase-1 (TK) in a blood sample. In normal cells, TK activity is hardly detectable, but in proliferating cells, the levels increase. Since the degree of TK activity is highly associated with the rate of cell proliferation, it is a particularly suitable biomarker for measuring tumor aggressiveness. DiviTum[®] has in several trials already successfully demonstrated clinical potential in evaluating and monitoring the efficacy of endocrine standard treatments for women with metastatic breast cancer. By providing key information for early identification of those patients not responding or resistant to their on-going treatment, DiviTum[®] presents a non-invasive and efficacious approach to monitoring and predicting responses to standard endocrine therapies.

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.

Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.




(c) 2020 Cision. All rights reserved., source Press Releases - English

01/18BIOVICA INTERNATIONAL : DiviTum«TKa in early treatment resistance trial
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTum«TK..
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
2020BIOVICA INTERNATIONAL : DiviTum«TKa included in new UK breast cancer study
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTum«TKa r..
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTum«TKa as an early an..
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
2020BIOVICA INTERNATIONAL : DiviTum«TKa Monitoring Capabilities Confirmed in SWOG St..
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
More news
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,62 M -4,62 M
Net cash 2021 134 M 16,0 M 16,0 M
P/E ratio 2021 -31,1x
Yield 2021 -
Capitalization 1 227 M 147 M 147 M
EV / Sales 2021 365x
EV / Sales 2022 25,6x
Nbr of Employees 21
Free-Float 75,2%
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 43,40 SEK
Spread / Highest target 137%
Spread / Average Target 54,4%
Spread / Lowest Target -28,6%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors